|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis predicted that there is a SPRY4-IT1/miR-101-3p/AMPK axis in GC progression.
|
31330497 |
2019 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
Adrenergic modulation of AMPK‑dependent autophagy by chronic stress enhances cell proliferation and survival in gastric cancer.
|
30896863 |
2019 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
LKB1-AMPK activation in GC cell lines was tumor suppressive, as metformin (an AMPK activator) inhibited GC cell growth in the CAB39L-silenced cells.
|
30054562 |
2018 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
The anti-gastric cancer mechanism of BBR might be involved in AMPK-HNF4α-WNT5A signaling pathway.
|
30405404 |
2018 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
MTDH-stimulated cancer resistance to 5-FU may be mediated through autophagy activated by the AMPK/ATG5 pathway in GC.
|
29635244 |
2018 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that CAMKK2 signals in gastric cancer through AMPK activation and suggest that CAMKK2 could be a novel therapeutic target in gastric cancer.
|
25756516 |
2015 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
BEFREE |
We identified HNF4α-WNT5A regulation in the cross-talk between the AMPK metabolic pathway and the WNT signaling pathway, and further identified WNT5A as a potential therapeutic target for GC.
|
24681952 |
2014 |
|
Malignant neoplasm of stomach
|
0.370 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The circRNA-miRNA-mRNA network was most involved in the MAPK, mTOR, AMPK, and WNT signaling pathways in Alzheimer's disease.
|
31834549 |
2020 |
|
Alzheimer's Disease
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that diet control to achieve euglycaemia in an insulin-deficient DM condition may be harmful because of the greater possibility of AD development through increased tau phosphorylation by AMPK activation in the hippocampus.
|
31799531 |
2020 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe largely nonoverlapping genetic determinants in AMPK genes for diabetes-/atherosclerosis-related traits, which reflect the metabolic pathways controlled by the enzyme.
|
31512724 |
2020 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe largely nonoverlapping genetic determinants in AMPK genes for diabetes-/atherosclerosis-related traits, which reflect the metabolic pathways controlled by the enzyme.
|
31512724 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study we showed that treatment with ouabain (25 nM) caused simultaneous activation of AMPK and Src signaling pathways in human lung cancer A549 cells and human breast cancer MCF7 cells.
|
31515527 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the pivotal role of AMPK in metabolism, whether ouabain affects cancer cell metabolism remains elusive.
|
31515527 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMPK is generally a tumor suppressor.However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development.
|
31787232 |
2020 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since AMPK is a direct regulator of tau phosphorylation, we hypothesized that strict diet control to achieve euglycaemia affects tau protein phosphorylation through increased AMPK activity in the hippocampus of DM rats.
|
31799531 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLF significantly improved skeletal muscle insulin resistance and mitochondrial function in db/db mice and L6 myocytes through AMPK-PGC-1α signaling pathway, and our findings support the therapeutic effects of MLF on type 2 diabetes.
|
31639486 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, possible mechanisms of antidiabetic activity of L-SGgly were identified as increasing GLP-1 levels and activating liver AMPK in T2DM rats.
|
31586692 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMPK is generally a tumor suppressor.However, once cancer arises, AMPK becomes a tumor promoter instead, driving cancer development.
|
31787232 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The expression levels of miR31, miR92a, KRAS oncogene, and the c-MYC transcription factor were subexpressed upon 72 h post-treatment with kaempferol-3-<i>O</i>-glycoside compared with the control without treatment (<i>P</i> < .05); in contrast, the tumor suppressor genes AMPK (∼4.85, <i>P</i> = .005) and APC (∼2.71, <i>P</i> = .066) tumor suppressors genes were overexpressed.
|
31441682 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The signaling pathway activated by metformin (LKB1/AMPK/mTOR) is implicated in tumor suppression in ApcMin/+ mice via metformin-induced reduction in polyp burden, increased ratio of pAMPK/AMPK, decreased pmTOR/mTOR ratio, and decreased pS6Ser235/S6Ser235 ratio in polyps.
|
31818851 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide new insights into LC role as an AMPK activator and anti-oxidative molecule in NAFLD.
|
31705397 |
2020 |